AGÕæÈ˹ٷ½

STOCK TITAN

Orchestra BioMed Holdings Inc SEC Filings

OBIO NASDAQ

Welcome to our dedicated page for Orchestra BioMed Holdings SEC filings (Ticker: OBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Clinical trial milestones, FDA pathway risks, and royalty-sharing details make Orchestra BioMed’s disclosures anything but light reading. If you have ever searched a 300-page 10-K for the next payment trigger with Medtronic or wondered when executives last sold shares ahead of pivotal data, you know the challenge.

Stock Titan solves that problem. Our platform delivers AI-powered summaries that turn dense text into plain English, so understanding Orchestra BioMed SEC documents with AI becomes practical. Whether you need an Orchestra BioMed quarterly earnings report 10-Q filing, an Orchestra BioMed 8-K material events explained, or the latest Orchestra BioMed insider trading Form 4 transactions, everything appears in one feed—updated in real time as soon as EDGAR posts.

What can you uncover?

  • Milestone revenue figures from partnership footnotes in the Orchestra BioMed annual report 10-K simplified
  • Trial cost run-rates and cash burn trends in each Orchestra BioMed earnings report filing analysis
  • Orchestra BioMed executive stock transactions Form 4 that flag buying or selling before catalyst events
  • Board pay packages within the Orchestra BioMed proxy statement executive compensation
  • Device safety updates filed as “Item 8.01â€� within an 8-K

Every document�10-K, 10-Q, 8-K, S-1, or Orchestra BioMed Form 4 insider transactions real-time—is automatically indexed, summarized, and linked to the original PDF. Save hours poring over medical-device jargon and focus on decisions instead. Complex filings, clarified.

Rhea-AI Summary

Eric S. Fain, a director of Orchestra BioMed Holdings, Inc. (OBIO), reported an acquisition of 5,760 shares of the company's common stock at a weighted-average price of $2.61 per share. Following this transaction the reporting person beneficially owns 71,709 shares indirectly through the Fain Living Trust. The filing identifies the purchase as multiple transactions aggregated to a weighted-average price and notes the reporting person is filing individually as a director. No derivative transactions, dispositions, or other changes in ownership are reported in this Form 4.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Orchestra BioMed Holdings, Inc. (OBIO) reporting person Darren Sherman, identified as President and Chief Operating Officer, acquired 3,000 shares of the company's common stock on 08/25/2025 at a price of $2.62 per share. Following the transaction, Mr. Sherman directly beneficially owns 926,837 shares. The Form 4 was signed by an attorney-in-fact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (OBIO), reported purchasing a total of 6,000 shares of the company's common stock on 08/21/2025 at a weighted-average price of $2.49 per share (individual trade prices ranged from $2.49 to $2.50). After the reported purchase, Mr. Hochman beneficially owns 651,460 shares directly and additional shares indirectly via multiple family trusts (total indirect positions listed: 449,331; 2,000; 2,000; 2,000; 3,140). The Form 4 was signed by an attorney-in-fact on 08/25/2025. The filing discloses insider buying by the CEO/chair but does not provide reasons for the transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Orchestra BioMed Holdings, Inc. insider filing shows Chief Financial Officer Andrew Taylor reported a non-derivative purchase of 2,000 shares of the company on 08/25/2025 at a price of $2.55 per share. Following the transaction, the reporting person beneficially owned 482,788 shares. The Form 4 was filed by a single reporting person and bears the reporting person's signature dated 08/25/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Orchestra BioMed Holdings, Inc. reported a net loss of $19.4 million for the three months ended June 30, 2025 and $38.1 million year-to-date, compared with $16.0 million and $29.4 million in the prior-year periods. Total revenue remained modest at $0.836 million for the quarter, driven by partnership and product sales, while research and development expense rose to $13.9 million in the quarter as the company advances multiple clinical programs.

On the balance sheet, cash and cash equivalents totaled $18.7 million and marketable securities $15.2 million, giving total assets of $42.8 million versus $76.2 million at year-end 2024. Stockholders' equity declined to $0.3 million. Operating cash used was $32.1 million for the six months ended June 30, 2025. Deferred revenue from the Terumo collaboration was $14.0 million, with approximately $4.5 million expected to be recognized in the next 12 months. Management states available capital (including subsequent proceeds) is sufficient to fund operations through at least one year from issuance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
quarterly report
-
Rhea-AI Summary

Orchestra BioMed Holdings, Inc. reported an award of 80,000 restricted stock units (RSUs) to reporting person Taylor Andrew Lawrence, identified as Chief Financial Officer, with an earliest transaction date of 08/07/2025. Each RSU represents a contingent right to one share of common stock and the reported acquisition was recorded at a price of $0 per RSU.

The RSUs vest in three tranches subject to the reporting person’s continuous service: 33.33% at 24 months, 33.33% at 30 months and 33.34% at 36 months after the grant date. After the award the reporting person beneficially owns 480,788 shares, reported as direct ownership. The Form 4 is signed by Andrew Taylor on 08/08/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
insider
Rhea-AI Summary

Aryeh Jason, a director of Orchestra BioMed Holdings, Inc. (OBIO), was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock, and the filing shows the reporting person beneficially owns 107,482 shares following the award.

The RSUs are scheduled to vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through that date. The transaction is reported as a non-derivative equity award (Transaction Code A) with a reported price of $0 and is held in a direct ownership form.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
insider
-
Rhea-AI Summary

Insider grant and holdings update: Darren Sherman, listed as a director and as President and Chief Operating Officer of Orchestra BioMed Holdings, Inc. (OBIO), was awarded 120,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to one share of common stock and the award was reported as acquired at a $0 price.

The RSUs vest over three years in three tranches: 33.33% at 24 months, 33.33% at 30 months and 33.34% at 36 months, subject to continued service. Following the reported transaction, the filing shows 923,837 shares beneficially owned by the reporting person in a direct ownership form.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
insider
-
Rhea-AI Summary

Orchestra BioMed Holdings (OBIO) director Pamela Ann Connealy was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to one share of common stock and the reported acquisition is recorded at a $0 price.

The RSUs are scheduled to vest on the one‑year anniversary of the grant date, subject to the reporting persons continuous service through that date. Following the award, Ms. Connealy beneficially owns 48,711 shares of common stock, held directly.

The filing lists Ms. Connealys relationship to the issuer as a director. No derivative securities or dispositions are reported in this Form 4.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
insider
Rhea-AI Summary

Orchestra BioMed Holdings director Mack John Prosper was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock and the award shows a per-unit price of $0. The RSUs are scheduled to vest on the one-year anniversary of the grant, subject to the reporting persons continuous service through that date. After this award the reporting person beneficially owns 40,286 shares on a direct basis.

The Form 4 shows the transaction as an acquisition (code A) and was filed by one reporting person. No derivative securities or additional transactions are reported in this filing and no other material details are provided.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
insider

FAQ

What is the current stock price of Orchestra BioMed Holdings (OBIO)?

The current stock price of Orchestra BioMed Holdings (OBIO) is $3 as of August 26, 2025.

What is the market cap of Orchestra BioMed Holdings (OBIO)?

The market cap of Orchestra BioMed Holdings (OBIO) is approximately 140.3M.
Orchestra BioMed Holdings Inc

NASDAQ:OBIO

OBIO Rankings

OBIO Stock Data

140.28M
39.91M
16.19%
34.98%
1.31%
Biotechnology
Surgical & Medical Instruments & Apparatus
United States
NEW HOPE